SCM Pharma’s pre-clinical capability will be housed in formulation and analytical laboratories at the University of Sunderland’s new science complex based near to the clinical trial manufacture’s existing MHRA-licensed facility.
Initially, the development and contract manufacturing organization (CDMO) is expected to offer developmental services for liquid formulations including emulsions and suspensions for parenteral, oral and topical administration using either proprietary or customers’ novel delivery systems.
SCM Pharma managing director Dianne Sharp said the work they have carried out with Mitovie has provided them with an ideal grounding of what to expect when introducing, managing and progressing such projects.
"With our track record of consistently supplying products for clinical trials and niche commercial markets, we can now support clients from start to finish, which means lower tech transfer costs, quicker time to market and our personable service throughout the process," Sharp said.